NADPH oxidase as a therapeutic target in Alzheimer's disease
Open Access
- 3 December 2008
- journal article
- review article
- Published by Springer Nature in BMC Neuroscience
- Vol. 9 (S2), S8
- https://doi.org/10.1186/1471-2202-9-s2-s8
Abstract
At present, available treatments for Alzheimer's disease (AD) are largely unable to halt disease progression. Microglia, the resident macrophages in the brain, are strongly implicated in the pathology and progressively degenerative nature of AD. Specifically, microglia are activated in response to both β amyloid (Aβ) and neuronal damage, and can become a chronic source of neurotoxic cytokines and reactive oxygen species (ROS). NADPH oxidase is a multi-subunit enzyme complex responsible for the production of both extracellular and intracellular ROS by microglia. Importantly, NADPH oxidase expression is upregulated in AD and is an essential component of microglia-mediated Aβ neurotoxicity. Activation of microglial NADPH oxidase causes neurotoxicity through two mechanisms: 1) extracellular ROS produced by microglia are directly toxic to neurons; 2) intracellular ROS function as a signaling mechanism in microglia to amplify the production of several pro-inflammatory and neurotoxic cytokines (for example, tumor necrosis factor-α, prostaglandin E2, and interleukin-1β). The following review describes how targeting NADPH oxidase can reduce a broad spectrum of toxic factors (for example, cytokines, ROS, and reactive nitrogen species) to result in inhibition of neuronal damage from two triggers of deleterious microglial activation (Aβ and neuron damage), offering hope in halting the progression of AD.Keywords
This publication has 95 references indexed in Scilit:
- Sinomenine, a natural dextrorotatory morphinan analog, is anti-inflammatory and neuroprotective through inhibition of microglial NADPH oxidaseJournal of Neuroinflammation, 2007
- An Update on the Amyloid HypothesisNeurologic Clinics, 2007
- Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: Implications for the role of nitration in the progression of Alzheimer's diseaseBrain Research, 2007
- Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammationNeuroscience, 2006
- Amyloid-β fibril formation is not necessarily required for microglial activation by the peptidesNeurochemistry International, 2005
- Possible Involvement of Small Oligomers of Amyloid-β Peptides in 15-Deoxy-Δ12,14 Prostaglandin J2-Sensitive Microglial ActivationJournal of Pharmacological Sciences, 2003
- Activation of NADPH Oxidase in Alzheimer's Disease BrainsBiochemical and Biophysical Research Communications, 2000
- Diphenyleneiodonium, an NAD(P)H Oxidase Inhibitor, also Potently Inhibits Mitochondrial Reactive Oxygen Species ProductionBiochemical and Biophysical Research Communications, 1998
- Dextromethorphan protects against cerebral injury following transient, but not permanent, focal ischemia in ratsLife Sciences, 1997
- Aggregation-related toxicity of synthetic β-amyloid protein in hippocampal culturesEuropean Journal of Pharmacology: Molecular Pharmacology, 1991